In harsh tones, the Alzheimer’s Association sharply criticized Biogen (BIIB) for the $56,000 price tag placed on its newly approved Alzheimer’s treatment, a move that threatens to embroil the biotech company and its medication in yet another national controversy.
Trending:
'Simply unacceptable': Alzheimer's Association blasts Biogen over the price of its new medicine